Prosecution Insights
Last updated: April 19, 2026
Application No. 18/159,719

DRUG DELIVERY DEVICE

Non-Final OA §103
Filed
Jan 26, 2023
Examiner
FREHE, WILLIAM R
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Sanofi-Aventis Deutschland GmbH
OA Round
3 (Non-Final)
60%
Grant Probability
Moderate
3-4
OA Rounds
3y 11m
To Grant
99%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allow Rate
229 granted / 382 resolved
-10.1% vs TC avg
Strong +41% interview lift
Without
With
+41.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
50 currently pending
Career history
432
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
51.2%
+11.2% vs TC avg
§102
19.6%
-20.4% vs TC avg
§112
23.4%
-16.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 382 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 09/30/2025 has been entered. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-6 and 15 are rejected under 35 U.S.C. 103 as being unpatentable over Harrington (USPGPub 2021/0069427) in view of Uber et al. (USPGPub 2017/0165427). Re Claim 1, Harrington teaches a drug delivery device (1, 2, 3) (Harrington Fig. 1) comprising: a housing (30) comprising a window (32) (Harrington ¶ 0043); and a syringe (11, 40a, 40b) contained in the housing (30) (Harrington Fig. 1; ¶ 0046), the syringe (11, 40a, 40b) comprising: a container (40a, 40b) containing a liquid medicament, the container (40a, 40b) comprising an aperture (12) at a distal end thereof and through which the liquid medicament can be dispensed (Harrington ¶ 0046); a stopper (43a, 43b) within the container (40a, 40b) (Harrington ¶ 0058), the stopper (43a, 43b) moveable between a first longitudinal position and a second longitudinal position relative to the container (40a, 40b) to cause dispensing of the liquid medicament through the aperture (12) (Harrington ¶ 0058). However, Harrington fails to teach at least one identifier identifying the liquid medicament, the at least one identifier arranged on a circumferential surface of the stopper and visible through the window. Uber teaches a syringe (200) comprising at least one identifier (210, 220) for identifying a liquid medicament (Uber ¶ 0054, 0057), the at least one identifier (210, 220) arranged on a circumferential surface of the stopper (204) (Uber ¶ 0054-0057), the configuration for properly identifying syringe contents and other identifying information about the syringe, such as instructions for using the syringe (Uber ¶ 0016). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have the syringe barrel of Harrington include at least one identifier identifying the liquid medicament, the at least one identifier arranged on a circumferential surface of the stopper as disclosed by Uber, the configuration for properly identifying syringe contents and other identifying information about the syringe, such as instructions for using the syringe (Uber ¶ 0016). Such a modification of Harrington would result in the identifier, as disclosed by Uber, being visible in the window (32) of Harrington for properly identifying syringe contents and other identifying information about the syringe, such as instructions for using the syringe (Uber ¶ 0016). Furthermore, Harrington encourages a user of the device to inspect the cartridge contents through the window (32) (Harrington ¶ 0043). Re Claim 2, Harrington in view of Uber teach all of the limitations of Claim 1. Harrington fails to teach wherein the at least one identifier is arranged at a distal end of the syringe. It is noted here that the identifier in Uber is arranged on a circumferential surface of the stopper (Uber ¶ 0054-0057). Therefore, as the stopper is depressed within the syringe, the at least one identifier (210, 220) is arranged at a distal end of the syringe (220), the configuration for properly identifying syringe contents and other identifying information about the syringe, such as instructions for using the syringe (Uber ¶ 0016). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have the at least one identifier of Harrington in view of Uber be arranged at the distal end of the syringe as disclosed by Uber, wherein the at least one identifier being arranged on the stopper naturally would result in the identifier being arranged at a distal end of the syringe as disclosed by Uber, wherein the identifier configured to be on a circumferential surface of the stopper is for properly identifying syringe contents and other identifying information about the syringe, such as instructions for using the syringe (Uber ¶ 0016). Re Claims 3 and 4, Harrington in view of Uber teach all of the limitations of Claim 1. Harrington further teaches wherein the syringe (11, 40a, 40b) further comprises a needle shield (20) comprising a hole (22) through which the liquid medicament is to be dispensed (Harrington Figs. 1 and 20-21 - wherein needle shield 20 has a bore 22 therethrough which accommodates needle 12), wherein the outer surface of the needle shield comprises a front face (21), and wherein the hole (22) is arranged on the front face (21) (as seen below in Harrington Annotated Fig. 21; ¶ 0047). PNG media_image1.png 280 250 media_image1.png Greyscale PNG media_image2.png 235 322 media_image2.png Greyscale Re Claim 5, Harrington in view of Uber teach all of the limitations of Claim 1. Harrington fails to teach wherein the at least one identifier comprises a printed surface. Uber teaches the at least one identifier (210, 220) comprising a printed surface for a user to identify the concentration of the medicament or a characteristic of the syringe (Uber ¶ 0052, 0054, 0057). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have the at least one identifier of Harrington in view of Uber to comprise a printed surface as disclosed by Uber for a user to identify the concentration of the medicament or a characteristic of the syringe (Uber ¶ 0052, 0054, 0057). Furthermore, if a technique has been used to improve one device, and a person of ordinary skill in the art would recognize that it would improve similar devices in the same way, using the technique is obvious unless its actual application is beyond that person's skill. KSR Int'l Co. V. Teleflex, Inc., 550 U.S. 398 (2007). In the present case, the technique of printing to a surface is well within the ordinary skill of the art based on the teachings of Uber (Uber ¶ 0052, 0054, 0057). Re Claim 6, Harrington in view of Uber teach all of the limitations of Claim 1. Harrington fails to teach wherein the at least one identifier comprises a laser marked surface. Uber teaches the at least one identifier (210, 220) comprising a laser marked surface for a user to identify the concentration of the medicament or a characteristic of the syringe (Uber ¶ 0054). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have the at least one identifier of Harrington in view of Uber to comprise a laser marked surface as disclosed by Uber for a user to identify the concentration of the medicament or a characteristic of the syringe (Uber ¶ 0054). Furthermore, if a technique has been used to improve one device, and a person of ordinary skill in the art would recognize that it would improve similar devices in the same way, using the technique is obvious unless its actual application is beyond that person's skill. KSR Int'l Co. V. Teleflex, Inc., 550 U.S. 398 (2007). In the present case, the technique of laser marking a surface is well within the ordinary skill of the art based on the teachings of Uber (Uber ¶ 0054). Re Claim 15, Harrington teaches a method comprising: disposing a syringe (11, 40a, 40b) in a housing (30) of a drug delivery device (1, 2, 3) (Harrington Fig. 1), the syringe (11, 40a, 40b) comprising a container (40a, 40b) containing a liquid medicament, the container (40a, 40b) comprising an aperture (12) at a distal end thereof and through which the liquid medicament can be dispensed (Harrington ¶ 0046), and a stopper (43a, 43b) within the container (40a, 40b), the stopper (43a, 43b) moveable between a first longitudinal position and a second longitudinal position relative to the container (40a, 40b) to cause dispensing of the liquid medicament through the aperture (12) (Harrington ¶ 0058), and the housing (30) further comprising a window (32) (Harrington ¶ 0043). However, Harrington fails to teach at least one identifier identifying the liquid medicament, the at least one identifier arranged on a circumferential surface of the stopper and visible through the window. Uber teaches a syringe (200) comprising at least one identifier (210, 220) for identifying a liquid medicament (Uber ¶ 0054, 0057), the at least one identifier (210, 220) arranged on a circumferential surface of the stopper (204) (Uber ¶ 0054-0057), the configuration for properly identifying syringe contents and other identifying information about the syringe, such as instructions for using the syringe (Uber ¶ 0016). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have the syringe barrel of Harrington include at least one identifier identifying the liquid medicament, the at least one identifier arranged on a circumferential surface of the stopper as disclosed by Uber, the configuration for properly identifying syringe contents and other identifying information about the syringe, such as instructions for using the syringe (Uber ¶ 0016). Such a modification of Harrington would result in the identifier, as disclosed by Uber, being visible in the window (32) of Harrington for properly identifying syringe contents and other identifying information about the syringe, such as instructions for using the syringe (Uber ¶ 0016). Furthermore, Harrington encourages a user of the device to inspect the cartridge contents through the window (32) (Harrington ¶ 0043). Claims 21 and 22 are rejected under 35 U.S.C. 103 as being unpatentable over Harrington (USPGPub 2021/0069427) in view of Uber et al. (USPGPub 2017/0165427) as applied to Claims 1 or 15 respectively above, and further in view of Sharp et al. (USPGPub 2007/0088285). Re Claims 21 and 22, Harrington in view of Uber teach all of the limitations of Claims 1 and 15 respectively. Harrington in view of Uber fail to teach wherein the at least one identifier is positioned between at least two sealing surfaces of the stopper. Sharp teaches a stopper (50) (Sharp Fig. 8) having at least two sealing surfaces, one at a distal most surface of the stopper and the other at a proximal most surface of the stopper (as seen in Sharp Fig. 8), the two sealing surfaces for aligning the stopper with markings on the syringe (Sharp ¶ 0004). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have configured the stopper of Harrington in view of Uber to have at least two sealing surfaces at a proximal end and distal end of the stopper as disclosed by Sharp for aligning the stopper with markings on the syringe (Sharp ¶ 0004). Furthermore, where the stopper of Harrington in view of Uber is modified as such, the at least one identifier of Harrington in view of Uber would be positioned between the at least two sealing surfaces of the stopper where the at least two sealing surfaces are arranged at a distal most and proximal most surface of the stopper (as seen in Sharp Fig. 8). Response to Arguments Applicant’s arguments with respect to Claims 1-6, 15 and 21-22 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Examiner concedes that the prior art in the rejection dated 05/30/2025 fails to teach “at least one identifier identifying the liquid medicament, the at least one identifier arranged on a circumferential surface of the stopper and visible through the window.” To obviate said limitation, examiner now relies upon secondary reference Uber. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to WILLIAM R FREHE whose telephone number is (571)272-8225. The examiner can normally be reached 10:30AM-7:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kevin Sirmons can be reached at 571-272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /WILLIAM R FREHE/Examiner, Art Unit 3783 /MICHAEL J TSAI/Supervisory Patent Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Jan 26, 2023
Application Filed
Feb 11, 2025
Non-Final Rejection — §103
May 16, 2025
Response Filed
May 24, 2025
Final Rejection — §103
Jul 30, 2025
Response after Non-Final Action
Aug 26, 2025
Examiner Interview Summary
Aug 26, 2025
Applicant Interview (Telephonic)
Sep 30, 2025
Request for Continued Examination
Oct 02, 2025
Response after Non-Final Action
Dec 24, 2025
Non-Final Rejection — §103
Mar 02, 2026
Applicant Interview (Telephonic)
Mar 02, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594378
PRESSURE RELIEF VALVE FOR DRUG DELIVERY DEVICE
2y 5m to grant Granted Apr 07, 2026
Patent 12551667
CATHETER, INFLATABLE BALLOON FOR A CATHETER
2y 5m to grant Granted Feb 17, 2026
Patent 12551618
SYSTEM AND METHOD FOR MITIGATING RISK IN AUTOMATED MEDICAMENT DOSING
2y 5m to grant Granted Feb 17, 2026
Patent 12551627
AUTO-INJECTOR
2y 5m to grant Granted Feb 17, 2026
Patent 12539123
METHODS AND DEVICES FOR BLOOD DISPLACEMENT-BASED LOCALIZED TREATMENT
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
60%
Grant Probability
99%
With Interview (+41.4%)
3y 11m
Median Time to Grant
High
PTA Risk
Based on 382 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month